ALC:NYE-Alcon AG (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 95.14

Change

0.00 (0.00)%

Market Cap

USD 46.93B

Volume

0.60M

Analyst Target

USD 65.36
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland. Address: Chemin de Blandonnet 8, Geneva, Switzerland, 1214

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-20 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

N/A

USD 70.45B
RMD ResMed Inc

N/A

USD 35.22B
BAX Baxter International Inc

N/A

USD 18.81B
AVTR Avantor Inc

N/A

USD 16.81B
TFX Teleflex Incorporated

N/A

USD 11.31B
ATR AptarGroup Inc

N/A

USD 11.20B
BLCO Bausch + Lomb Corp

N/A

USD 7.26B
STVN Stevanato Group SpA

N/A

USD 4.99B
WRBY Warby Parker Inc

N/A

USD 1.86B
INFU InfuSystems Holdings Inc

N/A

USD 0.15B

ETFs Containing ALC

CHSRI:SW UBS ETF (CH) - MSCI Switz.. 5.01 % 0.00 %

N/A

N/A
CHSRIA:SW UBS ETF (CH) MSCI Switzer.. 5.01 % 0.00 %

N/A

N/A
CHSR:XETRA UBS(Lux)Fund Solutions .. 5.01 % 0.00 %

N/A

USD 0.17B
CHSRII:SW UBS(Lux)Fund Solutions .. 4.98 % 0.00 %

N/A

N/A
XSLI:SW Xtrackers SLI UCITS ETF 1.. 4.37 % 0.00 %

N/A

USD 0.30B
SLICHA:SW UBS ETF (CH) – SLI® (C.. 4.37 % 0.00 %

N/A

USD 32,912.73B
SMIEX:SW iShares SLI UCITS ETF (DE.. 4.34 % 0.00 %

N/A

USD 5,933.96B
CSSLI:SW iShares SLI® ETF (CH) 4.32 % 0.00 %

N/A

USD 0.60B
CBCH30:SW 3.78 % 0.00 %

N/A

N/A
ESDG:LSE Amundi Index Solutions - .. 3.52 % 0.00 %

N/A

USD 0.20B
MIVB:XETRA Amundi Index Solutions - .. 3.49 % 0.00 %

N/A

USD 2.10B
ACU7:XETRA Amundi Index Solutions - .. 3.49 % 0.00 %

N/A

USD 0.13B
ESRG:LSE Amundi Index Solutions - .. 3.48 % 0.00 %

N/A

USD 2.17B
XSMC:SW Xtrackers Switzerland UCI.. 3.31 % 0.00 %

N/A

USD 0.48B
XSMI:SW Xtrackers Switzerland UCI.. 3.31 % 0.00 %

N/A

USD 1.27B
XSMI:XETRA Xtrackers Switzerland UCI.. 3.31 % 0.00 %

N/A

N/A
SMICHA:SW UBS ETF (CH) – SMI® (C.. 3.29 % 0.00 %

N/A

USD 17,142.72B
CSSMI:SW iShares SMI® ETF (CH) 3.24 % 0.00 %

N/A

USD 2.07B
ESRU:LSE Amundi Index Solutions - .. 3.12 % 0.00 %

N/A

N/A
ESDU:LSE Amundi Index Solutions - .. 3.09 % 0.00 %

N/A

N/A
CHEUR:SW UBS(Lux)Fund Solutions .. 2.79 % 0.00 %

N/A

N/A
CHEURD:SW UBS(Lux)Fund Solutions .. 2.79 % 0.00 %

N/A

N/A
CHUSD:SW UBS(Lux)Fund Solutions .. 2.79 % 0.00 %

N/A

N/A
CHUSDD:SW UBS(Lux)Fund Solutions .. 2.79 % 0.00 %

N/A

N/A
SPYH:XETRA SPDR® MSCI Europe Health.. 2.70 % 0.00 %

N/A

USD 0.66B
ESIH:XETRA iShares MSCI Europe Healt.. 2.70 % 0.00 %

N/A

USD 0.60B
STWX:SW SPDR® MSCI Europe Health.. 2.69 % 0.00 %

N/A

USD 0.74B
SPICHA:SW UBS ETF (CH) – SPI® (C.. 2.62 % 0.00 %

N/A

USD 131,872.43B
SXDPEX:SW iShares STOXX Europe 600 .. 2.54 % 0.00 %

N/A

USD 0.44B
CHSPI:SW iShares Core SPI® ETF (C.. 2.51 % 0.00 %

N/A

USD 3.46B
HEAE:LSE SPDR® MSCI Europe Health.. 2.50 % 0.00 %

N/A

N/A
CHDIV:SW UBS ETF (CH) - MSCI Switz.. 2.31 % 0.00 %

N/A

USD 1,244,681.59B
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.26 % 0.00 %

N/A

N/A
EWL iShares MSCI Switzerland .. 0.00 % 0.47 %

N/A

N/A
LNGR 0.00 % 0.50 %

N/A

N/A
RNDM 0.00 % 0.65 %

N/A

N/A
FLSW Franklin FTSE Switzerland.. 0.00 % 0.09 %

N/A

USD 0.06B
HLTH:LSE SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

N/A
XSDR:LSE Xtrackers MSCI Europe Hea.. 0.00 % 0.00 %

N/A

USD 0.24B
UC93:LSE UBS MSCI Switzerland 20/3.. 0.00 % 0.00 %

N/A

USD 8.63M
UC94:LSE UBS(Lux)Fund Solutions .. 0.00 % 0.00 %

N/A

USD 0.07B
EUSRI:PA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 2.17B
STW:PA SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

USD 0.72B
C030:F Lyxor DJ Switzerland Tita.. 0.00 % 0.00 %

N/A

USD 0.01B
DBXS:F Xtrackers - Switzerland U.. 0.00 % 0.00 %

N/A

N/A
DXS0:F Xtrackers - SLI UCITS ETF 0.00 % 0.00 %

N/A

N/A
DXSE:F Xtrackers Stoxx Europe 60.. 0.00 % 0.00 %

N/A

N/A
EL4X:F Deka DAXplus Maximum Divi.. 0.00 % 0.00 %

N/A

N/A
EXI1:F iShares SLI UCITS ETF (DE.. 0.00 % 0.00 %

N/A

N/A
EXV4:F iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

N/A
EXV5:F iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

N/A
MIVB:F Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

N/A
SPYH:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

N/A
C030:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 0.13B
DBXS:XETRA Xtrackers - Switzerland U.. 0.00 % 0.00 %

N/A

USD 1.34B
DXS0:XETRA Xtrackers SLI UCITS ETF 1.. 0.00 % 0.00 %

N/A

USD 0.26B
DXSE:XETRA Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

USD 0.14B
EL4X:XETRA Deka DAXplus Maximum Divi.. 0.00 % 0.00 %

N/A

USD 0.29B
EXI1:XETRA iShares SLI UCITS ETF (DE.. 0.00 % 0.00 %

N/A

USD 0.37B
EXV4:XETRA iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

USD 0.70B
1391:TSE 0.00 % 0.00 %

N/A

N/A
SW2CHA:SW UBS(Lux)Fund Solutions .. 0.00 % 0.00 %

N/A

USD 0.45B
SW2CHB:SW UBS(Lux)Fund Solutions .. 0.00 % 0.00 %

N/A

USD 1.44B
SW2UKD:SW UBS(Lux)Fund Solutions .. 0.00 % 0.00 %

N/A

USD 0.04B
SWICHA:SW UBS ETF (CH) – MSCI Swi.. 0.00 % 0.00 %

N/A

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Swi.. 0.00 % 0.00 %

N/A

USD 226,274.21B
CEFA Global X S&P Catholic Val.. 0.00 % 0.00 %

N/A

USD 0.01B
AGNG Global X Aging Population.. 0.00 % 0.00 %

N/A

USD 0.06B
ESIH:LSE iShares MSCI Europe Healt.. 0.00 % 0.00 %

N/A

USD 0.66B
ESIH:F Ishares VI PLC - Ishares .. 0.00 % 0.00 %

N/A

USD 0.67B
S2HGBD:SW UBS(Lux)Fund Solutions .. 0.00 % 0.00 %

N/A

USD 0.07B
SWEUAH:SW UBS ETF (CH) – MSCI Swi.. 0.00 % 0.00 %

N/A

USD 226,274.20B
S2HGBA:SW UBS(Lux)Fund Solutions .. 0.00 % 0.00 %

N/A

USD 8.45M

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.79% 84% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.79% 84% B 78% C+
Trailing 12 Months  
Capital Gain 31.21% 89% A- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.21% 89% A- 70% C-
Trailing 5 Years  
Capital Gain 63.75% 75% C 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.75% 75% C 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 11.29% 68% D+ 70% C-
Dividend Return 11.53% 63% D 65% D
Total Return 0.24% 11% F 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 17.18% 89% A- 60% D-
Risk Adjusted Return 67.09% 100% F 82% B
Market Capitalization 46.93B 93% A 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.